Director, Center for Anxiety and Traumatic Disorders, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts
Email: mhpollack@bics.bwh.harvard.edu
Mark H. Pollack, MD, has disclosed that he has received grants for clinical research from Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth. He has also served as an advisor for Bristol-Myers Squibb, Cephalon, Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche Laboratories, Sepracor, UCB Pharma, and Wyeth. Dr. Pollack is on the speakers' bureau for Forest Laboratories, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, UCB Pharma, and Wyeth.